Expert-based collaborative analysis of the situation and prospects of biomarker test implementation in oncology in Spain

• Jorge Mestre-Ferrándiz ^[1] ; Blanca Franch Camino ^[4] ; Álvaro Hidalgo ^[5] ; Alicia del Llano Núñez-Cortés ^[4] ; Juan Ernesto del Llano Señarís ^[4] ; Blanca Lumbreras ^[2] ; David Beas Pedraza ^[6] ; Roberto Nuño-Solinís ^[7] ; Luis Paz-Ares ^[8] ; Santiago Ramón y Cajal ^[9] ; Miguel Javier Rodríguez ^[3]
  1. [1] Universidad Carlos III de Madrid

     Universidad Carlos III de Madrid

     Madrid, España

     
  2. [2] Universidad Miguel Hernández de Elche

     Universidad Miguel Hernández de Elche

     Elche, España

     
  3. [3] Hospital Universitario Central de Asturias

     Hospital Universitario Central de Asturias

     Oviedo, España

     
  4. [4] Fundación Gaspar Casal, Madrid
  5. [5] Fundación Weber, Madrid
  6. [6] Janssen España, Madrid
  7. [7] AES, Madrid
  8. [8] Hospital Universitario 12 Octubre, Madrid
  9. [9] Hospital de Vall d’Hebron, Barcelona

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 26, Nº. 4, 2024, págs. 985-990
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Purpose Biomarkers as screening for precision medicine is a fundamental step. The purpose of this article is twofold. First, to highlight the existing barriers in the implementation of Precision Medicine in Spain, with a special emphasis on barriers in access to the determination of biomarkers. Second, to provide a Roadmap that can help implement Precision Medicine equitably at the national level and optimize the use of biomarkers.

    Methods A systematic review of literature (SRL) and a focus group (FG) with multidisciplinary experts has been carried out in 2023. Participants were contacted individually, and discourse analysis was processed anonymously.

    Results We carried out a quantitative (SRL) and a qualitative approach (FG). The discourse analysis and roadmap were sent individually to each expert for approval.

    Conclusions The potential of Precision Medicine has not been fulfilled in Spain. While several regional initiatives are in place, a national plan or strategy around Precision Medicine and use of biomarkers is lacking. In a general context of rapid progress at a global and European level, including the 2021 Europe’s Beating Cancer Plan, it is time to define and implement a National Plan to make the promise come true. While some comparable countries within Europe – such as the UK or France – are mature enough to adopt such strategies, in Spain there is still a long way to go. We consider that the different strands of work outlined in the Roadmap can be used as basis for such purpose.